{"id":286,"date":"2021-07-05T16:24:41","date_gmt":"2021-07-05T16:24:41","guid":{"rendered":"https:\/\/aspree.org\/usa\/?page_id=286"},"modified":"2026-08-28T02:54:54","modified_gmt":"2026-08-28T02:54:54","slug":"for-researchers","status":"publish","type":"page","link":"https:\/\/aspree.org\/usa\/for-researchers\/","title":{"rendered":"For researchers"},"content":{"rendered":"

[et_pb_section fb_built=”1″ custom_padding_last_edited=”off|desktop” _builder_version=”4.16″ background_color=”#26619A” custom_padding=”0px||0px||false|false” custom_padding_tablet=”24vh||2vh||false|false” background_color_gradient_direction_tablet=”360deg” background_color_gradient_stops_tablet=”#2b87da 49%|#29c4a9 79%” background_color_gradient_start_position_tablet=”49%” background_color_gradient_end_position_tablet=”79%” background_size_tablet=”cover” background_position_tablet=”center_right” background_position_phone=”center_right” locked=”off” global_colors_info=”{}”][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#26619a” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”2_5,3_5″ use_custom_gutter=”on” gutter_width=”1″ make_equal=”on” custom_padding_last_edited=”on|tablet” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” width=”100%” max_width=”100%” custom_padding=”0px||0px|4%|false|false” custom_padding_tablet=”0px|||0%|false|false” custom_padding_phone=”” locked=”off” global_colors_info=”{}”][et_pb_column type=”2_5″ _builder_version=”4.16″ custom_padding=”30px||||false|false” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_ds_breadcrumbs module_class=”light” _builder_version=”4.5.1″ _module_preset=”default” locked=”on” global_colors_info=”{}”][\/et_pb_ds_breadcrumbs][et_pb_text _builder_version=”4.16″ header_font=”|700|||||||” header_font_size=”42px” header_line_height=”1.15em” background_layout=”dark” width=”80%” max_width=”520px” module_alignment=”center” custom_margin=”3em||20px||false|false” custom_margin_tablet=”3em||||false|false” custom_margin_phone=”” custom_margin_last_edited=”on|desktop” header_font_size_tablet=”34px” header_font_size_phone=”24px” header_font_size_last_edited=”on|desktop” module_alignment_tablet=”” module_alignment_phone=”” module_alignment_last_edited=”on|tablet” global_colors_info=”{}”]<\/p>\n

FOR RESEARCHERS<\/h1>\n

[\/et_pb_text][et_pb_text _builder_version=”4.16″ text_font_size=”24px” background_layout=”dark” width=”80%” max_width=”520px” module_alignment=”center” custom_margin=”||40px||false|false” custom_padding=”||||false|false” text_font_size_tablet=”20px” text_font_size_phone=”16px” text_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

The ASPREE trial of low-dose aspirin showed that 100mg of enteric coated aspirin taken daily did not extend life free of disability in older adults.<\/p>\n

ASPREE XT is the continuing longitudinal follow-up of ASPREE participants\u00a0<\/a>seeking opportunities to prevent illness and disability in this age group.<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”3_5″ _builder_version=”4.16″ background_image=”https:\/\/aspree.org\/wp-content\/uploads\/sites\/3\/2021\/07\/asprinedit.jpg” custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_code _builder_version=”4.16″ _module_preset=”default” height=”34em” height_tablet=”250px” height_phone=”250px” height_last_edited=”on|phone” global_colors_info=”{}”][\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ specialty=”on” padding_right_2=”0px” padding_left_2=”0px” padding_top_bottom_link_2=”false” padding_left_right_link_2=”true” module_class=”texture-left” _builder_version=”4.16″ _module_preset=”default” inner_max_width=”80%” custom_margin=”||||false|false” custom_padding=”||90px||false|false” border_color_bottom=”#bdbec0″ global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Anchors” _builder_version=”4.16″ text_font=”||||||||” text_text_color=”#26619a” header_font=”|||on|||||” header_2_font=”|||on|||||” header_2_font_size=”32px” header_3_line_height=”2em” text_font_size_tablet=”28px” text_font_size_phone=”24px” text_font_size_last_edited=”on|phone” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|phone” locked=”off” global_colors_info=”{}”]<\/p>\n

THE ASPREE PROJECT<\/h2>\n

 <\/p>\n

\u2192\u00a0ASPREE Sub-studies<\/a><\/h3>\n

\u2192\u00a0ASPREE Publications<\/a><\/h3>\n

\u2192\u00a0Data Access<\/a><\/h3>\n

\u2192\u00a0PI updates<\/a><\/h3>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”2_3″ specialty_columns=”2″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_row_inner admin_label=”PUT CONTENT BELOW AS A TEXT AND IMAGES” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” custom_padding=”|0px||0px|true|true” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”ASPREE clinical trial & XT study summary” _builder_version=”4.16″ _module_preset=”default” text_font=”||||||||” header_font=”||||||||” global_colors_info=”{}”]<\/p>\n

THE ASPREE CLINICAL TRIAL\u00a0 (March 2010 – June 2017)<\/h3>\n

ASPirin in Reducing Events in the Elderly (ASPREE) was a large community-based clinical trial undertaken between 2011 and 2017 involving older adults in the US and Australia. 19,114 individuals participated: 2,411 from centers across the US and 16,703 participants from across south eastern Australia. While the Australian participants were mainly Caucasians aged 70 and above, approximately half of US participants were ethnic minorities aged 65 years and older. At recruitment all participants were free of overt cardiovascular disease, dementia and physical disability.
The primary objective of ASPREE was to determine whether low-dose aspirin (100mg) could prolong disability-free survival, i.e. life free of dementia or persistent physical disability. Secondary objectives aimed to determine whether low-dose aspirin reduced the incidence of cardiovascular disease, cognitive decline, depression, cancer, physical disability and major bleeding episodes. The principal results were published in the New England Journal of Medicine<\/a> in September 2018.<\/p>\n

 <\/p>\n

THE ASPREE-XT FOLLOW-UP STUDY\u00a0 (June 2017 – current)<\/h3>\n

The ASPREE-XT study is continuing to follow-up<\/em> the ASPREE participants following<\/em> cessation of the randomized, aspirin or placebo, treatment phase. The large majority of participants are no longer taking aspirin. This phase of the study is aiming to determine whether any impacts of a prolonged course of aspirin therapy are delayed, as has been suggested with some cancers.\u00a0 ASPREE-XT, in conjunction with various sub-studies is also examining whether genetic, lifestyle or environmental factors that may contribute to the maintenance of health and identify other opportunities to prevent illness and disability in this age group.<\/p>\n

The Berman Center for Outcomes and Clinical Research<\/a> leads the ASPREE project in the USA, and Monash University leads in Australia.<\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ background_color=”#26619a” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”At a Glance” _builder_version=”4.16″ _module_preset=”d100a70a-4a1b-4c0a-852d-deb7ebdb8d36″ header_font=”|600||on|||||” header_text_align=”left” header_2_font=”|600||on|||||” header_2_text_align=”left” header_2_font_size=”32px” text_orientation=”center” background_layout=”dark” custom_margin=”||0px||false|false” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

AT A gLANCE<\/h2>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” make_equal=”on” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”5fc07e0a-53a2-4b20-aac9-883fa2ab9fbb” background_color=”#ffffff” box_shadow_style=”preset1″ box_shadow_blur=”8px” global_colors_info=”{}”][et_pb_code admin_label=”Image (as background)” _builder_version=”4.16″ _module_preset=”default” background_image=”https:\/\/aspree.org\/wp-content\/uploads\/sites\/3\/2021\/07\/230_Mobile_Labs_Study_Participants_352288.jpg” width=”100%” height=”220px” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][\/et_pb_code][et_pb_text admin_label=”Project Features” _builder_version=”4.16″ _module_preset=”default” text_line_height=”1.8em” header_2_font=”|600|||||||” header_4_text_align=”center” background_color=”#ffffff” custom_margin=”0px||0px||true|false” custom_padding=”5%|5%|5%|5%|true|true” locked=”off” global_colors_info=”{}”]<\/p>\n

\u00a0Project Features<\/strong><\/h3>\n